Credits: 1.50 CME / CE / CPE
Medical Learning Institute, Inc.
Solving the Multimodal Puzzle of Head & Neck Cancer in the Immunotherapy Era: How Evidence is Driving Practice Changes
27 March, 2018
Credits: 1.50 CME
Medical Learning Institute, Inc.
Moving in Leaps and Bounds Towards Precision Immuno-Oncology: Latest Biomarker Strategies to Guide Patient Selection and Maximize the Potential of Cancer Immunotherapies
2 March, 2018
Credits: 1.50 CME / CE / CPE
Medical Learning Institute, Inc.
Understanding the Impact of Immunotherapy on Head and Neck Cancer: A Look at the Science, Practice, and Future of Multimodal Treatment
Understanding the Impact of Immunotherapy on Head and Neck Cancer: A Look at the Science, Practice, and Future of Multimodal TreatmentStart
Activity Description and Educational ObjectivesTreatment options for patients with squamous cell cancer of the head and neck (SCCHN), including recurrent/metastatic SCCHN, have expanded with the rapid integration of immunotherapy into modern oncology. In particular, checkpoint blockade has become an important component of multimodal head and neck cancer (HNC) care. Currently, researchers are attempting to answer the question of how exactly immune checkpoint blockade will pair with existing treatment modalities, such as radiotherapy, in the HNC setting; and what this further integration of immune therapy will mean for patients with recurrent/metastatic or locally advanced HNC. This activity features insight from expert clinicians as they attempt to answer these issues in HNC while offering thoughts on a patient’s experience of several modes of therapy, including radiation and immune treatment; based on a recent live symposium held at the 2017 American Society of Radiation Oncology (ASTRO) Annual Meeting.
Upon completion of this activity, participants will be able to:
- Describe updated efficacy and safety evidence on the use of immunotherapy in a range of SCCHN treatment settings, including recurrent/metastatic or locally advanced disease, among others
- Summarize evidence on novel combination options for SCCHN, including immune combinations, immunotherapy radiotherapy, and other multimodal approaches
- Recommend treatment with immunotherapy for eligible patients with SCCHN, including individuals eligible for clinical trial–based treatment
- Recognize and manage unique response dynamics or adverse events in patients with SCCHN receiving immunotherapy, radiotherapy-immunotherapy, or other multimodal combinations
Target AudienceThis activity has been designed to meet the educational needs of radiation, medical and surgical oncologists, advanced practice nurses, pharmacists, and other clinicians involved in the management of patients with squamous cell cancer of the head and neck.
Nursing Education Purpose StatementThe purpose of this activity is to improve knowledge and competence of nurses concerning the treatment of squamous cell cancer of the head and neck.
Requirements for Successful CompletionIn order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME/CE/CPE credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Enduring Material
Release and Expiration Dates: November 02, 2017 - November 01, 2018
Time to Complete: 90 minutes
Faculty & Disclosure / Conflict of Interest PolicyBefore the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE/CPE activity during the past 12 months.
Course Director and ModeratorRobert L. Ferris, MD, PhD
Director, UPMC Hillman Cancer Center
Hillman Professor of Oncology
Associate Vice Chancellor for Cancer Research
Co-Director, Tumor Microenvironment Center
Professor of Otolaryngology, of Immunology, and of Radiation Oncology
Robert L. Ferris, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck & Co., Inc.; and VentiRx Pharmaceuticals.
Advisory Board for Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; EMD Serono, Inc.; Lilly; Merck & Co., Inc.; Pfizer; and PPD (Benitec Biopharma).
Robert L. Ferris, MD, PhD, does intend to discuss either non-FDA approved or investigational use for the following products/devices: several immune therapies currently in testing for various SCHNN populations, including durvalumab, nivolumab, pembrolizumab, lirilumab, epacadostat, and other immune-stimulating therapies.
FacultyEzra Cohen, MD, FRCPC, FASCO
Professor, Division of Hematology/Oncology, Department of Medicine
UC San Diego
Co-director, San Diego Center for Precision Immunotherapy
Associate Director for Translational Science
UC San Diego Moores Cancer Center
Co-leader, Solid Tumor Therapeutics Program
Co-director, Head and Neck Cancer Center of Excellence
La Jolla, California
Ezra Cohen, MD, FRCPC, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca; Bristol-Myers Squibb; Eisai Inc.; Human Longevity, Inc.; Merck & Co., Inc.; and Pfizer.
Ezra Cohen, MD, FRCPC, FASCO, does intend to discuss either non-FDA approved or investigational use for the following products/devices: several immune therapies currently in testing for various SCHNN populations, including durvalumab, nivolumab, pembrolizumab, lirilumab, epacadostat, and other immune-stimulating therapies.
Quynh-Thu Le, MD, FACR, FASTRO
Katharine Dexter McCormick & Stanley McCormick Memorial Professor
Professor and Chair
Department of Radiation Oncology
Quynh-Thu Le, MD, FACR, FASTRO, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb.
Grant/Research Support from Amgen Inc.; RedHill; and Varian Medical Systems, Inc.
Quynh-Thu Le, MD, FACR, FASTRO, does intend to discuss either non-FDA approved or investigational use for the following products/devices: several immune therapies currently in testing for various SCHNN populations, including durvalumab, nivolumab, pembrolizumab, lirilumab, epacadostat, and other immune-stimulating therapies.
CME ReviewerVishwanath Sathyanarayanan, MD, DM
Bangalore, Karnataka, India
Vishwanath Sathyanarayanan, MD, DM, has no financial interests/relationships or affiliations in relation to this activity.
Nurse ReviewerBobbie Perrin, RN, OCN
Harrington Cancer Center
Bobbie Perrin, RN, OCN, has no financial interests/relationships or affiliations in relation to this activity.
CPE ReviewerNancy Nesser, JD, PharmD
Oklahoma Health Care Authority
Oklahoma City, OK
Nancy Nesser, JD, PharmD, has no financial interests/relationships or affiliations in relation to this activity.
Medical DirectorCarmine DeLuca
PVI, PeerView Institute for Medical Education
Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.
DisclaimerThe information provided at this CME/CE/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
Providership, Credit & Support
PhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NursesMedical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider Number 15106, for 1.5 contact hours.
PharmacistsThe Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this application-based activity provides for 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-17-014-H01-P.
ProvidershipThis CME/CE/CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
SupportThis activity is supported through educational grants from Bristol-Myers Squibb and Merck & Co., Inc.
Collaboration StatementThis activity was developed in collaboration with the Head and Neck Cancer Alliance (HNCA).
Disclosure of Unlabeled UseThe faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.
Copyright © 2000-2017, PeerView
2 November, 2017